期刊
RHEUMATOLOGY INTERNATIONAL
卷 36, 期 12, 页码 1649-1656出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00296-016-3569-1
关键词
Annexin A2; Antiphospholipid antibodies; Primary antiphospholipid syndrome; Tumor necrosis factor alpha
类别
Antiphospholipid syndrome (APS) is characterized by thromboses and/or pregnancy losses. Laboratory criterion for the diagnosis of APS is the presence of antiphospholipid antibodies (anticardiolipin, anti-beta2-glycoprotein I (a beta 2gpI) and lupus anticoagulant). On the one hand, the latest classification criteria for the diagnosis of APS emphasized that thrombotic manifestations of the syndrome should be without any signs of an inflammatory process, while on the other hand, some recent reports have suggested that APS is a pro-inflammatory state. This article is focused on the importance of TNF-alpha and annexin A2 (anxA2) for patients with vascular (thrombotic) manifestations of the primary APS. The classic antithrombotic and antiplatelet therapy does not protect APS patients from the development of recurrent thrombosis. Therefore, an urgent need for the introduction of new therapeutic approaches in the treatment of APS patients is obvious. This review provides a rationale for the necessity for the use of immunomodulatory medications that could interfere with beta 2gpI binding to its receptor(s), such as anxA2, and/or inhibit TNF-alpha activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据